- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
ERBB4 predesign siRNASynthetic RNA
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| RI11826 | 5 OD 400 ul | 13-15 days | $ 110.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
ERBB4 predesign siRNA - Additional info | |
| Gene ID | 2066 |
| Gene Symbol | ERBB4 |
| Other Names HER4, MGC138404, p180erbB4, ERBB4 | |
| Format HPLC purified siRNA is supplied as a dried pellet in nmol quantities. | |
| Storage Maintain refrigerated at 2-8°C for up to one week. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
ERBB4 predesign siRNA - Related products
AP3122a: Phospho-HER4-Y1162 Antibody
AP3124a: Phospho-HER4-Y1188 Antibody
RI11826: ERBB4 predesign siRNA
BP3122a: Phospho-HER4-Y1162 Antibody Blocking Peptide
BP3124a: Phospho-HER4-Y1188 Antibody Blocking Peptide
BP7631a: ErbB4 Antibody (N-term) Blocking Peptide
BP7631b: ErbB4 Antibody (C-term) Blocking Peptide
AJ1342a: HER4 (ErbB4) Antibody
AJ1342b: HER4 (ErbB4) Antibody (C-term)
AJ1342c: HER4 (ErbB4) Antibody Phospho (pY1162)
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
This gene is a member of the Tyr protein kinase family and the epidermal growth factor receptor subfamily. It encodes a single-pass type I membrane protein with multiple cysteine rich domains, a transmembrane domain, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. Mutations in this gene have been associated with cancer. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized.
REFERENCES
The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Rokicki J, et al. Mol Cancer, 2010 Jun 15. PMID 20550710. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Andersson U, et al. Acta Oncol, 2010 Aug. PMID 20446891. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. Rose JE, et al. Mol Med, 2010 Jul-Aug. PMID 20379614. ErbB4 regulates the timely progression of late fetal lung development. Liu W, et al. Biochim Biophys Acta, 2010 Jul. PMID 20303366. Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours. Srirajaskanthan R, et al. Oncol Rep, 2010 Apr. PMID 20204273.
